Evaxion A/S, a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, reported its first quarter 2025 financial results, showing no revenue compared to $51,000 in the same period of 2024. The company recorded a net loss of $1.58 million for the first quarter of 2025, compared to a net income of $1.194 million in the first quarter of 2024. The operating loss for the period was $3.868 million, an improvement from the $4.396 million loss reported in the first quarter of 2024. In terms of business updates, Evaxion highlighted the continued development of its lead asset, EVX-01, with the ongoing phase 2 trial on track for a two-year readout in the second half of 2025, and the first patient in a one-year trial extension being dosed in May. The company also mentioned ongoing discussions with the European Investment Bank (EIB) regarding the conversion of €3.5 million of its €7 million loan into an equity-type instrument, expected to finalize in the second quarter of 2025. This conversion aims to increase equity by $3.7 million and improve financial flexibility. Evaxion's financial outlook remains solid, with a cash runway extending to mid-2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.